According to a study published in AIDS, increased human immunodeficiency virus (HIV) testing was cost-saving or cost-effective across cities in the U.S. Targeted PrEP for high-risk men who have sex with men was cost-saving in Miami and cost-effective in Atlanta, Baltimore, and Los Angeles. Researchers found that interventions made to improve antiretroviral therapy initiation gave greater value than other treatment engagement interventions but found that no single intervention was projected to reduce HIV incidence by more than 10.1 percent in any city.
Researchers identified and estimated previously-documented scale of delivery and costs for 16 evidence-based interventions from the Center for Disease Control and Prevention (CDC)’s Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention. Using a model calibrated for six U.S. cities, they estimate averted HIV infections, quality-adjusted life-years gained and incremental cost-effectiveness ratios for each intervention and city compared to the status quo over a 20-year time period.
From the BC Centre of Excellence in HIV/AIDs (acquired immonodeficiency syndrome) Mr. Emanuel Krebs, Mr. Xiao Zang, also from Simon Fraser University, Benjamin Enns, Ms. Jeong Min, and Dr. Bohdan Nosyk were co-authors of the paper. Dr. Czarina Behrends from Weill Cornell Medical College, Dr. Carlos Del Rio from Emory University School of Medicine, Dr. Julia Dombrowski from the University of Washington, Dr. Daniel Feaster from the University of Miami Department of Public Health Science, Dr. Kelly Gebo from Johns Hopkins School of Medicine, Dr. Matthew Golden from Washington University, Dr. Brandon Marshall from Brown University, Dr. Lisa Metsch from Columbia University, Dr. Bruce Schackman Weill Cornell Medical College, Dr. Steven Shoptaw from the UCLA, and Dr. Steffanie Strathdee from UC San Diego also served as co-authors.Friday Letter Submission, Publish on January 10